Hepatoid Adenocarcinoma of the Lung With EGFR Mutation and the Response to Tyrosine Kinase Inhibitor

被引：0
|
作者：
Chen, H. [1 ]
Wang, W. [2 ]
Li, X. [1 ]
Xu, C. [3 ]
Zhu, Y. [1 ]
Du, K. [1 ]
Fang, M. [2 ]
机构：
[1] Zhejiang Rongjun Hosp, Jiaxing, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Fujian Canc Hosp, Fuzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Hepatoid adenocarcinoma; EGFR mutation; tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.02
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [31] Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma
    Shiao, Hui-Yi
    Hsu, Tsu-An
    Lin, Wen-Hsing
    Yang, Tsong-Toh
    Hsieh, Hui-Fang
    Chen, Chiung-Tong
    Yeh, Teng-Kuang
    Hsieh, Hsing-Pang
    CANCER RESEARCH, 2014, 74 (19)
  • [32] Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient
    Hu, Yijuan
    Xiao, Lili
    Yang, Nong
    Zhang, Yongchang
    THORACIC CANCER, 2019, 10 (05) : 1252 - 1255
  • [33] Correlation between Efficacy of the EGFR Tyrosine Kinase Inhibitor and Serum Tumor Markers in Lung Adenocarcinoma Patients
    Pan, Jin Bing
    Hou, Yu Hong
    Zhang, Guo Jun
    CLINICAL LABORATORY, 2014, 60 (09) : 1439 - 1447
  • [34] A case with small-cell transformation after treatment with EGFR tyrosine kinase inhibitor for lung adenocarcinoma
    Osoegawa, Atsushi
    Hashimoto, Takafumi
    Yohei, Takumi
    Miyuki, Abe
    Shuji, Suehiro
    Michiyo, Miyawaki
    Kenji, Sugio
    ANNALS OF ONCOLOGY, 2015, 26 : 138 - 139
  • [35] The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
    Wu, Shang-Gin
    Liu, Yi-Nan
    Tsai, Meng-Feng
    Chang, Yih-Leong
    Yu, Chong-Jen
    Yang, Pan-Chyr
    Yang, James Chih-Hsin
    Wen, Yueh-Feng
    Shih, Jin-Yuan
    ONCOTARGET, 2016, 7 (11) : 12404 - 12413
  • [36] Hepatoid adenocarcinoma of the lung with EGFR and TP53 mutation: a case report and literature review
    Dutta, A.
    Nayak, S. S.
    Karuvandan, N.
    Shetty, O. A.
    VIRCHOWS ARCHIV, 2024, 485 : S439 - S439
  • [37] The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma
    Zhu, You-cai
    Wang, Wen-xian
    Zhang, Qu-xia
    Xu, Chun-wei
    Zhuang, Wu
    Du, Kai-qi
    Chen, Gang
    Lv, Tang-feng
    Song, Yong
    CLINICAL LUNG CANCER, 2019, 20 (01) : E73 - E76
  • [38] Correlation of EGFR and KRAS mutation status, response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and survival with histologic subtypes of adenocarcinoma of the lung.
    Hussain, S
    Zakowski, MF
    Kris, MG
    Ladanyi, M
    Pao, W
    Riely, G
    Rizvi, N
    Gomez, JE
    Miller, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 640S - 640S
  • [39] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
    Su-Hee Cho
    Lee Chun Park
    Jun Ho Ji
    Silvia Park
    Deok Won Hwang
    Ji Yean Lee
    Yoon-La Choi
    Jung-Ho Han
    Jong-Mu Sun
    Jin Seok Ahn
    Keunchil Park
    Myung-Ju Ahn
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 315 - 320
  • [40] Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
    Cho, Su-Hee
    Park, Lee Chun
    Ji, Jun Ho
    Park, Silvia
    Hwang, Deok Won
    Lee, Ji Yean
    Choi, Yoon-La
    Han, Jung-Ho
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 315 - 320
12345